コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inhibit the pathobiology that is specific to inflammatory breast cancer.
2 women with HER2-positive locally advanced or inflammatory breast cancer.
3 ing tumor type, and provide a novel model of inflammatory breast cancer.
4 the breast with lymph node metastasis and in inflammatory breast cancer.
5 erts tumor-suppressive effects in aggressive inflammatory breast cancer.
6 No patient had inflammatory breast cancer.
7 that were reflected in actual cases of human inflammatory breast cancer.
8 atients with inflammatory and those with non-inflammatory breast cancer.
9 ars for stage II and III disease and 42% for inflammatory breast cancer.
10 antimetastatic effects in highly aggressive inflammatory breast cancer and propose ERB and the ident
11 or neoadjuvant therapy include patients with inflammatory breast cancer and those in whom residual di
12 tratified by operable, locally advanced, and inflammatory breast cancer, and by oestrogen and/or prog
13 tuzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into
14 ive invading and matched non-invading SUM149 inflammatory breast cancer cells were enriched using thi
15 th a surrounding collagen matrix seeded with inflammatory breast cancer cells, which induce tumor ang
16 hat distinguish between inflammatory and non-inflammatory breast cancer, diagnosis of inflammatory br
17 cancer-two of whom were classified as having inflammatory breast cancer-had partial responses (PRs).
18 group and others suggests that patients with inflammatory breast cancer have significantly reduced ov
19 rge cell lymphoma, renal cell carcinoma, and inflammatory breast cancer, have been shown to activate
20 the motility of SUM cells derived from human inflammatory breast cancer (IBC) cells and RhoC-overexpr
21 or the first time that FOXP3 is expressed in inflammatory breast cancer (IBC) cells, SUM149 (triple n
35 No studies have investigated the etiology of inflammatory breast cancer (IBC), the most lethal form o
40 inics dedicated to the care of patients with inflammatory breast cancer in the USA and other countrie
42 Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patie
43 Studies using a human xenograft model of inflammatory breast cancer, MARY-X, demonstrated the equ
44 I propose that the unique presentation of inflammatory breast cancer might require specific, ident
45 women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab sign
47 d invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or DCIS (when breast-conserv
48 d invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or ductal carcinoma in situ
49 Society of Surgical Oncology, Morgan Welch Inflammatory Breast Cancer Program, The University of Te
51 non-inflammatory breast cancer, diagnosis of inflammatory breast cancer relies entirely on the existe
52 Moreover, patients with ErbB2-overexpressing inflammatory breast cancers responded to lapatinib monot
54 levels of N3(IC) exhibited tumors resembling inflammatory breast cancer that frequently metastasized.
55 emotherapy-naive patients with metastatic or inflammatory breast cancer that were evaluated for an ex
56 y relegates all patients with non-metastatic inflammatory breast cancer to stage 3, regardless of tum
57 ing with clinical criteria characteristic of inflammatory breast cancer to subcategory T4d, which imm
58 rticle on somatic mutations in patients with inflammatory breast cancer treated in a Phase II clinica
59 is in two animal models of breast cancer: an inflammatory breast cancer xenograft in nude mice and He